PATIENTS treated with one of the non-vitamin K antagonist oral anticoagulants (NOACs), namely Pfizer's Eliquis (apixaban), Boehringer Ingelheim's Pradaxa (dabigatran) or Bayer's Xarelto (rivaroxaban), can rest easy to learn that these drugs have a strong safety record even in the presence of a non-valvular atrial fibrillation (AF) comorbidity.
The findings came from the largest-ever real-world analysis of the US Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among over 180,000 patients treated with NOACs versus warfarin.
In this analysis Eliquis was associated with a significantly lower risk of stroke or systemic embolism and lower rate of major bleeding than patients treated with warfarin.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Mar 17